NCT00000960

Brief Summary

To determine whether the rate of HIV transmission from mother to infant can be reduced by continuous oral zidovudine (AZT) treatment to HIV infected pregnant women, intravenous AZT during childbirth, and oral AZT treatment of the newborn infant from birth to six weeks of age. The study is also designed to evaluate the safety of AZT for both the pregnant woman and the newborn infant. No method exists to prevent transmission of HIV from an infected mother to her newborn infant. Giving an antiviral agent (such as AZT) to the mother and to the newborn could in theory decrease the risk of infection to the newborn by reducing the exposure of the fetus to maternal virus, or by preventive treatment of the fetus before exposure.

Trial Health

85
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,496

participants targeted

Target at P75+ for phase_3 hiv-infections

Geographic Reach
2 countries

62 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Completion

Last participant's last visit for all outcomes

June 1, 1994

Completed
5.4 years until next milestone

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

October 29, 2021

Status Verified

October 1, 2021

First QC Date

November 2, 1999

Last Update Submit

October 28, 2021

Conditions

Keywords

PregnancyPregnancy Complications, InfectiousPrenatal Exposure Delayed EffectsAdministration, OralAIDS-Related ComplexZidovudine

Interventions

Eligibility Criteria

Age1 Day - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Concurrent Medication:
  • Allowed for infants:
  • Treatment for signs of drug withdrawal (e.g., phenobarbital, chlorpromazine, tincture of opium, paregoric, or Valium).
  • Treatment for nonserious conditions (e.g., syphilis treatment, hepatitis B vaccine).
  • All essential supportive treatment for conditions that are nonlife threatening as deemed by the on-site pediatrician.
  • Acetaminophen.
  • Standard immunizations.
  • Allowed for women:
  • Pneumocystis prophylaxis as indicated.
  • Topical steroids. Parenteral and oral steroids for 6 or fewer days.
  • Concurrent Treatment:
  • Allowed for pregnant woman:
  • Blood transfusion for anemia (hemoglobin less than 7 g/dl).
  • Allowed for infant:
  • \- Blood transfusions for anemia except if attributed to study drug.
  • +6 more criteria

You may not qualify if:

  • Co-existing Condition:
  • Infants with the following conditions or symptoms are excluded:
  • Requiring treatment for hyperbilirubinemia (except phototherapy).
  • Concurrent Medication:
  • Excluded:
  • Infants:
  • Antiretroviral drugs or vaccines.
  • Excluded during current pregnancy:
  • Zidovudine (AZT).
  • Other antiretroviral agents (e.g., rCD4, CD4-IgG, d4T, didanosine (ddI), dideoxycytidine (ddC)), passive immunotherapy (e.g., HIVIG), anti-HIV vaccines, cytolytic chemotherapeutic agents.
  • Corticosteroids for equal to or more than 7 days.
  • Patients with the following are excluded:
  • Evidence of preexisting fetal anomalies that may (1) result in a high probability that the fetus/infant will not survive to the end of the study period (e.g., anencephaly, renal agenesis, or Potter's syndrome); or (2) increase the fetal tissue concentration of zidovudine (AZT) or its metabolites to a toxic level (e.g., neural tube or ventral wall defects).
  • Baseline sonogram completed within 28 days prior to randomization that demonstrates 2nd trimester findings of anencephaly or oligohydramnios, or 3rd trimester findings of unexplained polyhydramnios, fetal hydrops, ascites or other evidence of preexisting in-utero anemia.
  • History of intolerance to AZT dose of 500 or less mg/day prior to this pregnancy that resulted in discontinuation of treatment for more than 4 weeks.
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (62)

Univ of Alabama at Birmingham Schl of Med / Pediatrics

Birmingham, Alabama, 35294, United States

Location

Univ of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

Location

UCSD Med Ctr / Pediatrics / Clinical Sciences

La Jolla, California, 920930672, United States

Location

Los Angeles County - USC Med Ctr

Los Angeles, California, 90033, United States

Location

UCLA Med Ctr / Pediatric

Los Angeles, California, 900951752, United States

Location

Harbor - UCLA Med Ctr / UCLA School of Medicine

Los Angeles, California, 905022004, United States

Location

San Francisco Gen Hosp

San Francisco, California, 94110, United States

Location

Children's Hosp of Denver

Denver, Colorado, 802181088, United States

Location

Univ of Connecticut / Farmington

Farmington, Connecticut, 06032, United States

Location

Univ of Connecticut Health Ctr

Farmington, Connecticut, 06032, United States

Location

Howard Univ Hosp

Washington D.C., District of Columbia, 20060, United States

Location

Univ of Miami (Pediatric)

Miami, Florida, 33161, United States

Location

Northwestern Univ Med School

Chicago, Illinois, 60611, United States

Location

Cook County Hosp

Chicago, Illinois, 60612, United States

Location

Univ of Illinois College of Medicine / Pediatrics

Chicago, Illinois, 60612, United States

Location

Chicago Children's Memorial Hosp

Chicago, Illinois, 606143394, United States

Location

Univ of Chicago Children's Hosp

Chicago, Illinois, 606371470, United States

Location

Tulane Univ / Charity Hosp of New Orleans

New Orleans, Louisiana, 701122699, United States

Location

Univ of Maryland at Baltimore / Univ Med Ctr

Baltimore, Maryland, 21201, United States

Location

Johns Hopkins Hosp - Pediatric

Baltimore, Maryland, 212874933, United States

Location

Johns Hopkins Hosp

Baltimore, Maryland, 21287, United States

Location

Children's Hosp of Boston

Boston, Massachusetts, 021155724, United States

Location

Boston City Hosp / Pediatrics

Boston, Massachusetts, 02118, United States

Location

Beth Israel Deaconess Med Ctr

Boston, Massachusetts, 02215, United States

Location

Baystate Med Ctr of Springfield

Springfield, Massachusetts, 01199, United States

Location

Univ of Massachusetts Med Ctr

Worcester, Massachusetts, 01655, United States

Location

Children's Hosp of Michigan

Detroit, Michigan, 48201, United States

Location

UMDNJ - New Jersy Med School

Newark, New Jersey, 071032714, United States

Location

Univ of Medicine & Dentistry of New Jersey / Univ Hosp

Newark, New Jersey, 071032714, United States

Location

Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl

Newark, New Jersey, 071072198, United States

Location

Children's Hosp at Albany Med Ctr

Albany, New York, 12208, United States

Location

SUNY - Brooklyn

Brooklyn, New York, 11203, United States

Location

SUNY / Health Sciences Ctr at Brooklyn / Pediatrics

Brooklyn, New York, 11203, United States

Location

Beth Israel Med Ctr / Pediatrics

New York, New York, 10003, United States

Location

Bellevue Hosp / New York Univ Med Ctr

New York, New York, 10016, United States

Location

Cornell Univ Med College

New York, New York, 10021, United States

Location

Mount Sinai Med Ctr / Pediatrics

New York, New York, 10029, United States

Location

Columbia Presbyterian Med Ctr

New York, New York, 10032, United States

Location

Univ of Rochester Medical Center

Rochester, New York, 14642, United States

Location

State Univ of New York at Stony Brook

Stony Brook, New York, 117948111, United States

Location

SUNY Health Sciences Ctr at Syracuse / Pediatrics

Syracuse, New York, 13210, United States

Location

Bronx Lebanon Hosp Ctr

The Bronx, New York, 10457, United States

Location

Albert Einstein College of Medicine

The Bronx, New York, 10461, United States

Location

Westchester Hosp

Valhalla, New York, 10595, United States

Location

Univ of North Carolina

Chapel Hill, North Carolina, 275997215, United States

Location

Carolinas Med Ctr

Charlotte, North Carolina, 28203, United States

Location

Duke Univ Med Ctr

Durham, North Carolina, 277103499, United States

Location

Univ of Cincinnati

Cincinnati, Ohio, 452670405, United States

Location

Children's Hosp of Philadelphia

Philadelphia, Pennsylvania, 191044318, United States

Location

Hosp of the Univ of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Thomas Jefferson Univ Hosp

Philadelphia, Pennsylvania, 191075098, United States

Location

Rhode Island Hosp / Brown Univ

Providence, Rhode Island, 02903, United States

Location

Med Univ of South Carolina

Charleston, South Carolina, 294253312, United States

Location

Saint Jude Children's Research Hosp of Memphis

Memphis, Tennessee, 381052794, United States

Location

Children's Med Ctr of Dallas

Dallas, Texas, 75235, United States

Location

Lyndon Baines Johnson Gen Hosp

Houston, Texas, 77030, United States

Location

Texas Children's Hosp / Baylor Univ

Houston, Texas, 77030, United States

Location

Children's Hosp of Seattle

Seattle, Washington, 98105, United States

Location

Ramon Ruiz Arnau Univ Hosp / Pediatrics

Bayamón, 00956, Puerto Rico

Location

Univ of Puerto Rico / Univ Children's Hosp AIDS

San Juan, 009365067, Puerto Rico

Location

UPR Children's Hosp / UPR School of Medicine

San Juan, 009365067, Puerto Rico

Location

San Juan City Hosp

San Juan, 009367344, Puerto Rico

Location

Related Publications (11)

  • Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM, Sullivan JL. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996 Nov 28;335(22):1621-9. doi: 10.1056/NEJM199611283352201.

    PMID: 8965861BACKGROUND
  • Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173-80. doi: 10.1056/NEJM199411033311801.

    PMID: 7935654BACKGROUND
  • Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, Coombs RW, Scott G, Van Dyke RB, Shearer WT, Jimenez E, Diaz C, Harrison DD, Delfraissy JF. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS. 1998 Oct 1;12(14):1805-13. doi: 10.1097/00002030-199814000-00012.

    PMID: 9792381BACKGROUND
  • Wiznia AA, Crane M, Lambert G, Sansary J, Harris A, Solomon L. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center. JAMA. 1996 May 15;275(19):1504-6.

    PMID: 8622226BACKGROUND
  • Rouzioux C. Prevention of maternal HIV transmission. Practical guidelines. Drugs. 1995;49 Suppl 1:17-24; discussion 38-40. doi: 10.2165/00003495-199500491-00006.

    PMID: 7614898BACKGROUND
  • Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, Boyer PJ, Keller M, Deveikis A, Stiehm ER, Bryson YJ. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA. 1996 Feb 28;275(8):599-605.

    PMID: 8594240BACKGROUND
  • Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999 Jan 13;281(2):151-7. doi: 10.1001/jama.281.2.151.

    PMID: 9917118BACKGROUND
  • Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, Rich K, Handelsman E, Diaz C, Pagano M, Smeriglio V, Kalish LA. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997 May 8;336(19):1337-42. doi: 10.1056/NEJM199705083361901.

    PMID: 9134873BACKGROUND
  • Frenkel LM, Cowles MK, Shapiro DE, Melvin AJ, Watts DH, McLellan C, Mohan K, Murante B, Burchett S, Bryson YJ, O'Sullivan MJ, Mitchell C, Landers D. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis. 1997 Apr;175(4):971-4. doi: 10.1086/514003.

    PMID: 9086162BACKGROUND
  • Newell ML, Gray G, Bryson YJ. Prevention of mother-to-child transmission of HIV-1 infection. AIDS. 1997;11 Suppl A:S165-72. No abstract available.

    PMID: 9451981BACKGROUND
  • Edathodu J, Halim MM, Dahham MB, Alrajhi AA. Mother-to-child transmission of HIV: experience at a referral hospital in Saudi Arabia. Ann Saudi Med. 2010 Jan-Feb;30(1):15-7. doi: 10.4103/0256-4947.59367.

MeSH Terms

Conditions

HIV InfectionsPregnancy Complications, InfectiousPrenatal Exposure Delayed EffectsAIDS-Related Complex

Interventions

Zidovudine

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsPrenatal InjuriesSlow Virus Diseases

Intervention Hierarchy (Ancestors)

ThymidinePyrimidine NucleosidesPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsDideoxynucleosidesDeoxyribonucleosidesNucleosidesNucleic Acids, Nucleotides, and Nucleosides

Study Officials

  • E Connor

    STUDY CHAIR
  • R Sperling

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Purpose
TREATMENT
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Study Completion

June 1, 1994

Last Updated

October 29, 2021

Record last verified: 2021-10

Locations